Preparation and characterization of a metered dose transdermal spray for testosterone

The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of testosterone and to characterize its efficacy. Testosterone release from a series of formulations was assessed in vitro. Skin from hairless mice was used in permeation exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Wangding Lu (Author), Huafei Luo (Author), Yubo Wu (Author), Zhuangzhi Zhu (Author), Hao Wang (Author)
Format: Book
Published: Elsevier, 2013-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7a99ba6bae9c4ab1a3938917c68f3094
042 |a dc 
100 1 0 |a Wangding Lu  |e author 
700 1 0 |a Huafei Luo  |e author 
700 1 0 |a Yubo Wu  |e author 
700 1 0 |a Zhuangzhi Zhu  |e author 
700 1 0 |a Hao Wang  |e author 
245 0 0 |a Preparation and characterization of a metered dose transdermal spray for testosterone 
260 |b Elsevier,   |c 2013-12-01T00:00:00Z. 
500 |a 2211-3835 
500 |a 2211-3843 
500 |a 10.1016/j.apsb.2013.10.003 
520 |a The objective of the present work was to develop a metered dose transdermal spray (MDTS) formulation for transdermal delivery of testosterone and to characterize its efficacy. Testosterone release from a series of formulations was assessed in vitro. Skin from hairless mice was used in permeation experiments with Franz diffusion cells. The spray pattern, pump seal efficiency, average weight per metered dose and dose uniformity were evaluated. An optimized formulation containing 10% (w/v) testosterone, 9% (v/v) azone and 91% (v/v) ethanol was based on good skin permeation and acceptable drug concentration and permeation enhancer (PE) content. A skin irritation study indicated that the formulation was non-irritating in a rat model. An in vivo pharmacokinetic study indicated that the optimized formulation showed a different plasma concentration-time profile from that of the commercially available product Testopatch®. The Testopatch® product demonstrated a more sustainable drug release. The evaluation of the testosterone MDTS indicated that it could deliver reproducible amounts of the formulation per actuation. The results obtained showed that the MDTS is a potential alternative therapeutic system for transdermal testosterone delivery. 
546 |a EN 
690 |a Metered dose transdermal spray 
690 |a Testosterone 
690 |a Transdermal vehicle 
690 |a Azone 
690 |a Permeability 
690 |a Pharmacokinetics 
690 |a Rat 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Acta Pharmaceutica Sinica B, Vol 3, Iss 6, Pp 392-399 (2013) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2211383513000944 
787 0 |n https://doaj.org/toc/2211-3835 
787 0 |n https://doaj.org/toc/2211-3843 
856 4 1 |u https://doaj.org/article/7a99ba6bae9c4ab1a3938917c68f3094  |z Connect to this object online.